Advertisement
New Zealand markets close in 3 hours 37 minutes
  • NZX 50

    11,880.62
    -65.81 (-0.55%)
     
  • NZD/USD

    0.5965
    +0.0015 (+0.26%)
     
  • NZD/EUR

    0.5558
    +0.0017 (+0.31%)
     
  • ALL ORDS

    7,849.90
    -87.60 (-1.10%)
     
  • ASX 200

    7,590.30
    -92.70 (-1.21%)
     
  • OIL

    83.89
    +0.32 (+0.38%)
     
  • GOLD

    2,339.10
    -3.40 (-0.15%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,284.54
    0.00 (0.00%)
     
  • NIKKEI 225

    37,651.38
    +22.90 (+0.06%)
     
  • NZD/JPY

    92.7830
    +0.2870 (+0.31%)
     

How Jazz Pharmaceuticals Is Positioned before Its Q2 2018 Results

How Jazz Pharmaceuticals Is Positioned before Its Q2 2018 Results

Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million in the first quarter, reflecting an ~18% YoY (year-over-year) rise. Xyrem and Vyxeos primarily pushed the company’s revenue growth in the quarter.